检索结果 - Yanshi Liu

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Complications of bone transport technique using the Ilizarov method in the lower extremity: a retrospective analysis of 282 consecutive cases over 10 years

    Complications of bone transport technique using the Ilizarov method in the lower extremity: a retrospective analysis of 282 consecutive cases over 10 years 由 Yanshi Liu, Maimaiaili Yushan, Zhenhui Liu, Jialin Liu, Chuang Ma, Aihemaitijiang Yusufu

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    A novel extracellular vesicles production system harnessing matrix homeostasis and macrophage reprogramming mitigates osteoarthritis

    A novel extracellular vesicles production system harnessing matrix homeostasis and macrophage reprogramming mitigates osteoarthritis 由 Tianqi Wang, Hongqi Zhao, Yi Zhang, Yanshi Liu, Jialin Liu, Ge Chen, Ke Duan, Li Zhong, James Hoi Po Hui, Jiyuan Yan

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    PCN38 Health-Related Quality of Life (QOL) in Monarch PLUS: A Phase 3 Trial of Abemaciclib PLUS Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant for Women with HR+/HER2- Advanced Breast Cancer (ABC)

    PCN38 Health-Related Quality of Life (QOL) in Monarch PLUS: A Phase 3 Trial of Abemaciclib PLUS Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant for Women with HR+/HER2- Adva... 由 Xianglin Hu, Q.Y. Zhang, Tao Sun, Yongmei Yin, Haotian Li, Min Yan, Zhongsheng Tong, Christina Oppermann, Yanshi Liu, Ruijie Han, N. Wang, Y.L. Zhang, W.L. Zhang, Zefei Jiang

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

    Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II... 由 F. Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Y. Chen, S. Yang, Jiawei Shi, Xiang Hu, Xiandong Lin, Q.Y. Zhang, J. Feng, Yi Ba, Yanshi Liu, W. Li, Yongqian Shu, Yi Jiang, Quan Li, J.W. Wang, H. T. Wu, Hui Feng, Sheng Yao, Rui‐Hua Xu

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

    Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study 由 Xiaoqing Yan, Ming Ye, Qing Zou, Peng Chen, Z.S. He, Bin Wu, Dalin He, Chao‐Hong He, Xue‐Yi Xue, Zhengguo Ji, Hui Chen, Xiaofeng Zhang, Yanshi Liu, Xiaodong Zhang, Cheng Fu, Dingkuan Xu, Qiu Ming-xing, J. Lv, Jian Huang, Xiaosong Ren, Ying Cheng, Weijun Qin, Xiaofang Zhang, Fangjian Zhou, Linlin Ma, Jianming Guo, De‐Gang Ding, Shuang Wei, Yi He, Hongqian Guo, Benkang Shi, Li Liu, Feng Liu, Zhiquan Hu, Xiaoping Jin, Li Yang, Shenghui Zhu, Jihong Liu, Yuehua Huang, Tao Xu, Ben Liu, Ting Sun, Zi-Wen Wang, H.W. Jiang, Dan Yu, Aiping Zhou, Jun Jiang, Guohui Luan, Chunlan Jin, Jianming Xu, Juntao Hu, Yanyou Huang, Jun Guo, Wei Zhai, Xinan Sheng

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: